{
    "nctId": "NCT05584644",
    "briefTitle": "A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer",
    "officialTitle": "Treatment Patterns and Clinical Outcomes Among Indian Patients Receiving Palbociclib Combinations for HR+/HER2- Advanced/Metastatic Breast Cancer in Real World Settings",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Breast Carcinoma, Breast Neoplasms, Breast Tumors, Cancer of Breast",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 150,
    "primaryOutcomeMeasure": "Number of Participants According to the Starting Dose of Palbociclib",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* HR+/HER2- breast cancer diagnosis with confirmed metastatic or advanced disease\n* Received palbociclib with aromatase inhibitor (as prescribed by the Physician) as initial endocrine therapy in postmenopausal metastatic breast cancer (MBC) patients or with fulvestrant in patients who have progressed on prior endocrine therapy\n* Patients on Leutinizing Hormone Releasing Hormone (LHRH) agonists for ovarian function suppression in pre- or perimenopausal stage only if prescribed palbociclib with fulvestrant\n* No prior or current enrolment in an interventional clinical trial for advanced/metastatic breast cancer\n* Minimum of 3 months of follow up data since palbociclib with fulvestrant initiation, or minimum of 6 months of follow up data since palbociclib with aromatase inhibitor initiation\n\nExclusion Criteria:\n\n* Cancers other than breast cancer\n* Male breast cancer\n* Visceral crisis",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}